MoonLake Immunotherapeutics AG, a clinical-stage biopharmaceutical company, closed its business combination with Helix Acquisition. The deal was approved by Helix’s shareholders in a March 31 vote. Helix said 8,080,845 shares were redeemed ahead of the vote, representing about 70% of the SPAC’s cash in trust.
That left Helix with about $34.5 million in trust, plus a $115 million PIPE. When announced in October, MoonLake was expected to receive about $230 million on the deal.
MoonLake trades on the Nasdaq under the ticker symbol MLTX, starting today. Read more.
